AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02184325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kiddi® Pharmaton Fizz, effervescent tablets
Study NCT02184325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kiddi® Pharmaton Fizz, effervescent tablets: marketed formula
Study NCT02184325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator product
Description: active substances: Vitamin A, Vitamin B1, Vitamin B2, Vitamin B5, Vitamin B6, Vitamin B12, Vitamin C, Vitamin D, Vitamin E, Manganese, Copper, Calcium, Magnesium, Phosphorous, Iron, Zinc, Sodium, Molybden
Study NCT04330950 — intervention group
Intervention type: OTHER
Intervention: Neurocognitive tests
Description: Preoperative: Battery of neurocognitive tests and questionnaires (MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey) Postoperative in PACU: NuDESC test Postoperative 30 days: 10 minute phone interview
Study NCT02576821 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neurological examinations
Study NCT02576821 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological examinations
Study NCT02576821 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical examinations
Study NCT02576821 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: MRI 3T
Study NCT02576821 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: MRI 7T
Study NCT01101152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate
Description: Tablets of 50 mg,100 mg; Dosing regimen: 50, 100, 200 mg/day; 1 week for each dose regimen;~1 tablet a day for doses of 50 and 100mg/day, and 2 tablets of 100mg for dose of 200mg/day
Study NCT00411996 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: indinavir/ritonavir
Description: IDV/r 600/100 mg BID + rifampicin OD for at least 2 weeks
Study NCT02740985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide 160 mg PO QD will be dosed per the approved package insert. The patient must receive enzalutamide according to the prescribing information during the DLT assessment period, Cycle 1 and Cycle 2. After Cycle 2 necessary enzalutamide dose modifications may follow institutional standard practice.~Enzalutamide is supplied as 40 mg soft gelatin capsules.
Study NCT02740985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Oleclumab 1500 mg will be given by IV infusion on Days 1 and 15 of each cycle.
Study NCT02740985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Patients in Cohort CC will receive docetaxel 75 mg/m² by IV infusion according to institutional standards of practice on Day 1 of each treatment cycle. If a patient's body surface area is greater than 2.2 m², the docetaxel dose will be adjusted to a body surface area of 2.2 m².~The patient should be pre-medicated with oral dexamethasone 8 mg (or equivalent) twice daily starting the day prior to treatment for a total of 3 days, or according to institutional standards of practice.
Study NCT02065284 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rhythmic Auditory Stimulation (RAS)
Description: Rhythmic Auditory Stimulation (RAS) is a music therapy technique that provides rhythmic auditory cues (like a beat) to help improve patients' movements, especially when walking.
Study NCT02605447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 months of dual antiplatelet therapy (DAPT)
Description: 3 months of P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) plus 15-months of aspirin
Study NCT02605447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYNERGY Stent System
Description: SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Study NCT00696865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2624
Description: oral suspension, 3 doses
Study NCT00696865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03628430 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine with epinephrine
Description: Local anesthesia with lidocaine with epinephrine
Study NCT01538199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near-infrared radiation via Transcranial LED Therapy
Description: The subject will lie down comfortably on a exam bed . The sites of application of TLT (left and right forehead) will be inspected for any skin lesions (e.g. laceration or signs of inflammation) which would contraindicate the treatment. The subject will wear protective eyewear in the form of goggles or eye pads.~The staff administering the TLT will be careful not to shine the light in or near the eyes of the subject. The two OLS devices will be secured in position with the use of a Hair Net. The delivery of the TLT is expected to last 20 min total (simultaneous application on the left and right forehead). The subject will be asked to rest for five minutes after the delivery of TLT. The skin at the sites of the application will be inspected again prior to dismissing the subject.
Study NCT01538199 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: The sham device does not emit near-infrared radiation.
Study NCT04772794 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fraction of inspired oxygen
Description: after induction of general anaesthesia, different fraction of inspired oxygen will be given to patient according to their group allocation
Study NCT04772794 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fraction of inspired oxygen
Description: after induction of general anaesthesia, different fraction of inspired oxygen will be given to patient according to their group allocation
Study NCT03628430 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: lidocaine with epinephrine
Description: Local anesthesia with lidocaine with epinephrine
Study NCT04940169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior cruciate ligament recontruction
Description: Firstly graft is harvested with help of arthroscopy femoral and tibial tunnels created then graft placed into tunnels
Study NCT03628430 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate
Description: sodium bicarbonate as adjuvant to lidocaine with epinephrine in Local anesthesia
Study NCT03628430 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: normal saline as adjuvant to lidocaine with epinephrine in Local anesthesia
Study NCT03664973 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus plane block
Description: Local anesthetic infusion though a peripheral nerve catheter placed on the 5th rib under the serratus plane
Study NCT03664973 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus plane block
Description: Local anesthetic infusion though a peripheral nerve catheter placed on the 5th rib under the serratus plane
Study NCT03224975 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fMRI
Description: During fMRI, patients and control group will have to thought to seven painful memories, seven emotional memories not painful, seven neutral memories. At every memory there is control test. It is to count backwards.
Study NCT03224975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: During fMRI, patients and control group will have to thought to seven painful memories, seven emotional memories not painful, seven neutral memories. At every memory there is control test. It is to count backwards.
Study NCT05487560 — intervention group
Intervention type: DRUG
Intervention: Esomezol Cap
Description: Esomezol Cap, Once daily administered per the locally approved product information
Study NCT02836301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control ending - Uplifting
Description: The control ending is emotionally uplifting. In this video, the decedent previously registered as an organ donor through online registration and discussed his decision with family. The scene cuts to the family affirming the deceased's wish. In the next scene, the donor family and recipient meet for the first time, ending with a plea from both parties for viewers to register for donation.
Study NCT02210871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: All subjects will be treated with a single subcutane (s.c., under the skin) injection of 0.5 mg semaglutide.
Study NCT03579368 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Symfony implantation
Description: Bilateral Symfony IOL Implantation
Study NCT02836301 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control ending - Uplifting
Description: The control ending is emotionally uplifting. In this video, the decedent previously registered as an organ donor through online registration and discussed his decision with family. The scene cuts to the family affirming the deceased's wish. In the next scene, the donor family and recipient meet for the first time, ending with a plea from both parties for viewers to register for donation.
Study NCT02836301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative Consequences Ending
Description: A sad ending where the decedent did not register or discuss their position with family; family is asked to consider donation as an option, but they do not agree. The patient with kidney failure misses the window of opportunity, and the final scene is of both families grieving at their respective family members' grave plots...a missed opportunity.
Study NCT02836301 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Negative Consequences Ending
Description: A sad ending where the decedent did not register or discuss their position with family; family is asked to consider donation as an option, but they do not agree. The patient with kidney failure misses the window of opportunity, and the final scene is of both families grieving at their respective family members' grave plots...a missed opportunity.
Study NCT02836301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unresolved Ending
Description: In this ending, the team checks for registration status, and while searching, the scene cuts to physicians discussing the death with family and whether they might consider preservation and organ donation. The video then cuts to the potential recipient and family hoping for a kidney transplant before it is too late. The story ends without resolution, leaving viewers to contemplate how they might respond in the same situation
Study NCT02836301 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unresolved Ending
Description: In this ending, the team checks for registration status, and while searching, the scene cuts to physicians discussing the death with family and whether they might consider preservation and organ donation. The video then cuts to the potential recipient and family hoping for a kidney transplant before it is too late. The story ends without resolution, leaving viewers to contemplate how they might respond in the same situation
Study NCT03739138 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4621
Description: MK-4621 is delivered via the JetPEI™ in vivo linear polyethylenimine nucleic acid delivery system as follows:~For Arm 1: administered intratumorally Q1W, on Days 1, 8, and 15 of each 21-day cycle.~For Arm 2: administered intratumorally Q1W, on Days 1, 8, and 15 of each 21-day cycle according to randomization.~For Arm 3: administered intratumorally Q3W, on Day 1 of each 21-day cycle. Range administered will depend upon allocation and be based on emerging safety data.
Study NCT02023437 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femtosecond laser cataract surgery
Description: The VICTUS lens fragmentation procedure is part of the femtosecond laser assisted cataract procedure, which generates precise cuts inside the cataractous lens, leading to a softening and fragmentation of the lens.
Study NCT02023437 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual cataract surgery
Description: Manual: manual group acts as a control group where the lens fragmentation are per-formed manually without femtosecond laser assisted lens fragmentation
Study NCT00753532 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 200mg of Palm vitamin E (tocotrienols) or placebo
Description: Individuals randomized in the (MRI+ve) and (MRI -ve) cohort respectively. In the MRI(+ve) cohort, 62 subjects received 200 mg softgels of Palm Vitamin E (tocotrienols) and 59 were assigned to placebo, taken orally twice a day for a study period of two years. In the MRI(-ve) cohort, 63 subjects received 200 mg softgels of Palm Vitamin E (tocotrienols) and 57 consumed placebo, taken twice a day for a follow up period of 1 year.
Study NCT04623944 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKX101 - CAR NK cell therapy
Description: NKX101 is an investigational allogeneic CAR NK product targeting NKG2D ligands on cancer cells. Part 2 will use the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of NKX101 as determined in Part 1.
Study NCT00587119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Oral Budesonide, 3 mg three times daily, will be given for 1 year.
Study NCT02874092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Study NCT04353037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1 HCQ
Description: Enrolled participants randomized in Group 1 receive the HCQ drug
Study NCT04353037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2 Placebo
Description: Enrolled participants randomized in Group 2 will receive a placebo drug
Study NCT02874092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX therapy
Study NCT01974284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: percutaneous ethanol ablation
Description: The volume of 99% ethanol to be injected is calculated using a standardized formula. Ethanol is instilled with a needle under ultrasound guidance after administration of local anesthesia.
Study NCT02229357 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OrniFlu® inactivated vaccine
Description: All subjects will receive a single dose of an H5 inactivated influenza vaccine after blood collection for immunology assays
Study NCT02339051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jumping on one leg
Study NCT03561311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote ischemic conditioning
Description: Remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mm Hg during the ischemic period (Patent No. CN200820123637.X, China)
Study NCT00913913 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccine
Description: DC Vaccine therapy 10E7 intranodally every cycle
Study NCT00913913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10mg/kg iv every 2 weeks
Study NCT00913913 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 18 MiU/m2 CI 5 days
Study NCT00913913 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IFN
Description: IFN 6 MiU subc TIW
Study NCT01137799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39393406
Description: 50mg nanosuspension (sort of liquid formulation) once daily (single dose)
Study NCT01137799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Once daily (single dose)
Study NCT01137799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39393406
Description: 200mg nanosuspension (sort of liquid formulation) once daily (single dose)
Study NCT01137799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39393406
Description: 100mg nanosuspension (sort of liquid formulation) once daily (single dose)
Study NCT01137799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39393406
Description: 10mg nanosuspension (sort of liquid formulation) once daily (single dose)
Study NCT01137799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39393406
Description: 30mg nanosuspension (sort of liquid formulation) once daily (single dose)
Study NCT03710564 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brolucizumab
Description: 6 mg/0.05mL solution for intravitreal injection
Study NCT03710564 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: 2 mg/0.05mL solution for intravitreal injection
Study NCT00878618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0837
Description: Extended-release tablets, test formulation. 2 tablets given in the morning for 6 days
Study NCT00878618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0837
Description: Extended-release tablets, reference formulation. 2 tablets given in the morning for 6 days
Study NCT05679830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol is a non-psychoactive cannabinoid obtained from the cannabis plant.
Study NCT01393353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Study NCT01393353 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: computer game
Study NCT02378714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.
Study NCT02378714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.
Study NCT02378714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BASC
Description: The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.~Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.
Study NCT02378714 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.
Study NCT02378714 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment
Description: Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.
Study NCT00572078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Cohort 1 200 mg po BID D1-5; Cohort 2 200 mg po BID; Cohort 3 400 mg po BID D1-5 Cohort 4 400 mg po BID
Study NCT03571191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab will be administered at 120 mg per dose every 4 weeks for six months, with loading doses on days 8 and 15 of month 1.
Study NCT02065050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: team-based care
Description: Patients in the eDMS arm are called at least every month for their diabetes treatment.
Study NCT06239948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: With Music
Description: each subject was placed in a TMS laboratory with music for 20 minutes
Study NCT06239948 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Without Music
Description: each subject was placed in a TMS laboratory without music for 20 minutes
Study NCT00726999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: oral gabapentin in load pre-op (15mg/kg) and maintenance 5mg/kg TID for 5 days or discharge
Study NCT00726999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00726999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Administered as needed
Study NCT00726999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: Administered as needed
Study NCT02616861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-1973
Description: IW-1973 Tablet
Study NCT02616861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo Tablet
Description: Matching placebo tablet
Study NCT00506727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts (ADDERALL XR)
Study NCT00506727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine hydrochloride